MA39354A1 - Compositions and methods for modulating complement factor b expression - Google Patents

Compositions and methods for modulating complement factor b expression

Info

Publication number
MA39354A1
MA39354A1 MA39354A MA39354A MA39354A1 MA 39354 A1 MA39354 A1 MA 39354A1 MA 39354 A MA39354 A MA 39354A MA 39354 A MA39354 A MA 39354A MA 39354 A1 MA39354 A1 MA 39354A1
Authority
MA
Morocco
Prior art keywords
compositions
expression
methods
complement factor
modulating complement
Prior art date
Application number
MA39354A
Other languages
French (fr)
Inventor
Susan Freier
Punit Seth
Thazha Prakash
Eric Swayze
Tamar Grossman
Michael Mccaleb
Andrew Watt
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Priority claimed from PCT/US2015/028916 external-priority patent/WO2015168635A2/en
Publication of MA39354A1 publication Critical patent/MA39354A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés, des composés et des compositions permettant de traiter, prévenir ou améliorer les symptômes d'une maladie associée à la dérégulation de la voie d'activation alterne du complément par l'administration d'un inhibiteur spécifique du facteur b du complément (cfb) à un sujet.The present invention provides methods, compounds and compositions for treating, preventing or ameliorating the symptoms of a disease associated with deregulation of the alternative complement activation pathway by administration of a specific factor b inhibitor. complement (cfb) to a subject.

MA39354A 2014-05-01 2015-05-01 Compositions and methods for modulating complement factor b expression MA39354A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987471P 2014-05-01 2014-05-01
PCT/US2015/028916 WO2015168635A2 (en) 2014-05-01 2015-05-01 Compositions and methods for modulating complement factor b expression

Publications (1)

Publication Number Publication Date
MA39354A1 true MA39354A1 (en) 2018-06-29

Family

ID=63586932

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46307A MA46307B1 (en) 2014-05-01 2015-05-01 Composition and methods for modulating expression of complement factor b
MA39354A MA39354A1 (en) 2014-05-01 2015-05-01 Compositions and methods for modulating complement factor b expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA46307A MA46307B1 (en) 2014-05-01 2015-05-01 Composition and methods for modulating expression of complement factor b

Country Status (1)

Country Link
MA (2) MA46307B1 (en)

Also Published As

Publication number Publication date
MA46307A1 (en) 2021-04-30
MA46307B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
MA38959A1 (en) Modulators of complement factor b
MA43518A (en) 3-AZABICYCLO [3.1.0] SUBSTITUTED HEXANES SERVING AS KETOHEXOKINASE INHIBITORS
BR112018004620A2 (en) kras expression modulators
EA201692204A1 (en) COMPOSITIONS AND METHODS OF MODULATING THE EXPRESSION OF COMPLEX B FACTOR
EA201692201A1 (en) CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7
MX2020012165A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
BR112018005223A2 (en) compounds and methods for modulating angiotensinogen expression
MX2018002049A (en) Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex.
EA201692177A1 (en) CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7
MA40240A (en) HETERARYL KINASE INHIBITION COMPOUNDS
BR112017028194A2 (en) diaciglycerol acyltransferase 2 modulators (dgat2)
EA201791096A1 (en) 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS GPR139 MODULATORS
EA201791711A1 (en) ANTIBODIES TO TRANSTIRETIN
EA201791710A1 (en) ANTIBODIES TO TRANSTIRETIN
MA34968B1 (en) ASYMMETRIC UREA AND MEDICAL USES THEREOF
EA201992248A1 (en) ANTI-C5a-ANTIBODIES AND THEIR APPLICATION
MX2023008839A (en) Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.
EA201791450A1 (en) 3,5-DIAMINOPYRAZOLES KINASE INHIBITORS
MY191993A (en) Use of isolated fractions of mastic gum for treating optic neuropathy
MA39354A1 (en) Compositions and methods for modulating complement factor b expression
MA43165B1 (en) RET INHIBITORS
EA201990671A1 (en) MUTANT ISOCITRATE DEHYDROGENASE INHIBITORS AND INCLUDING THEIR COMPOSITIONS AND METHODS
EA201990393A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 USED FOR TREATING VARIOUS DISEASES AND DISORDERS
CR20190329A (en) MODULATORS OF COMPLEMENT FACTOR Bi